1-3 of 3
Nuria Marquez
Close
Sort by
Journal Articles

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

CME Clinical Trials & Observations
Sylvie D. Freeman, Abin Thomas, Ian Thomas, Robert K. Hills, Paresh Vyas, Amanda Gilkes, Marlen Metzner, Niels Asger Jakobsen, Alison Kennedy, Rachel Moore, Nuria Marquez Almuina, Sarah Burns, Sophie King, Georgia Andrew, Kathleen M. E. Gallagher, Rob S. Sellar, Paul Cahalin, Duruta Weber, Mike Dennis, Priyanka Mehta, Steven Knapper, Nigel H. Russell
Journal: Blood
Blood (2023) 142 (20): 1697–1707.
https://doi.org/10.1182/blood.2023020630
Published: 2023
Includes: Supplemental data
Journal Articles

A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results

Sylvie D Freeman, Abin Thomas, Ian Thomas, Paresh Vyas, Amanda Gilkes, Marlen Metzner, Niels Asger Jakobsen, Alison Kennedy, Amy Moore, Nuria Marquez Almuina, Sarah Burns, Sophie King, Georgia M. Andrew, Kathleen M.E. Gallagher, Rob Sellar, Paul Cahalin, Duruta Weber, Mike Dennis, Priyanka Mehta, Steve Knapper, Nigel H. Russell
Journal: Blood
Blood (2022) 140 (Supplement 1): 532–533.
https://doi.org/10.1182/blood-2022-162245
Published: 2022
Journal Articles

Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling

Paul S. Hole, Joanna Zabkiewicz, Chinmay Munje, Zarabeth Newton, Lorna Pearn, Paul White, Nuria Marquez, Robert K. Hills, Alan K. Burnett, Alex Tonks, Richard L. Darley
Journal: Blood
Blood (2013) 122 (19): 3322–3330.
https://doi.org/10.1182/blood-2013-04-491944
Published: 2013
Includes: Supplemental data